GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » EV-to-FCF

CVRx (CVRX) EV-to-FCF : -6.94 (As of May. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CVRx's Enterprise Value is $274.99 Mil. CVRx's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.61 Mil. Therefore, CVRx's EV-to-FCF for today is -6.94.

The historical rank and industry rank for CVRx's EV-to-FCF or its related term are showing as below:

CVRX' s EV-to-FCF Range Over the Past 10 Years
Min: -14.05   Med: -3.71   Max: 1.03
Current: -6.94

During the past 5 years, the highest EV-to-FCF of CVRx was 1.03. The lowest was -14.05. And the median was -3.71.

CVRX's EV-to-FCF is ranked worse than
100% of 367 companies
in the Medical Devices & Instruments industry
Industry Median: 27.49 vs CVRX: -6.94

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), CVRx's stock price is $10.12. CVRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.980. Therefore, CVRx's PE Ratio for today is At Loss.


CVRx EV-to-FCF Historical Data

The historical data trend for CVRx's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx EV-to-FCF Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -3.71 -6.45 -15.06

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.45 -2.43 -5.36 -5.84 -15.06

Competitive Comparison of CVRx's EV-to-FCF

For the Medical Devices subindustry, CVRx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVRx's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CVRx's EV-to-FCF falls into.



CVRx EV-to-FCF Calculation

CVRx's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=274.990/-39.612
=-6.94

CVRx's current Enterprise Value is $274.99 Mil.
CVRx's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CVRx  (NAS:CVRX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CVRx's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.12/-1.980
=At Loss

CVRx's share price for today is $10.12.
CVRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.980.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CVRx EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CVRx's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CVRx (CVRX) Business Description

Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445